Ruxolitinib for Polycythemia Vera Intolerant or Resistant to Hydroxyurea : Episode 3

Objectives and Study Design of MAJIC-PV

May 8, 2024

By Gabriela Hobbs, MD
Timothy Mok, PharmD, BCPS, BCOP

Opinion

Video

Experts on polycythemia vera provide a comprehensive overview of the objectives and study design of the MAJIC-PV clinical trial, highlighting key endpoints.

EP: 1.Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera

EP: 2.The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance

Now Viewing

EP: 3.Objectives and Study Design of MAJIC-PV

EP: 4.Inside MAJIC-PV: A Closer Look at the Patient Population

EP: 5.Key Findings from MAJIC-PV

EP: 6.Safety Analysis and Interpreting Results from MAJIC-PV

EP: 7.Key Takeaways Following MAJIC-PV

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!